One tiny undiscovered biotech gem making waves this weekend is going
to be featured next week (July 8th) on NBC Television and it could
literally explode like CTIC, DNDN and so many other small cap
biotechs. Click right here for the news release referencing the July
8th @ 12pm EDT episode on NBC featuring Viral Genetics (VRAL)-
http://www.cnbc.com/id/31569575

Viral Genetics (VRAL) is a biotechnology company developing the VGV-1
injectable drug for the treatment of HIV/AIDS.

Check out this amazing video documentary on Viral Genetics and the
VGV-1 injectable drug during Phase I, II and III clinical trials in
South Africa @ http://www.youtube.com/watch?v=Jf1mQ6cxQNg

This is a pretty unique (and hopefully lucurative) situation to find
outabout the show before it airs.

The reason I started buying shares was because of the television show
but I’m actually considering letting some of my shares ride for like
2+ years because VRAL hasn’t even announced their IND yet or their FDA
Phase I initiation yet in the United States.

And do you want to know one of the the best parts? Although Wall
Street isn’t valuing the stock too well because they haven’t entered
into FDA trials at the moment, VRAL has already completed 5 successful
trials including Phases I, III & III in South Africa (HIV Capital of
the World).

This leads me to believe it could be a prime drug for FDA Fast Track
Approval so what would normally take 4-6 years for FDA Approval could
be a lot less (but of course that’s just my speculation).

Good luck to all!